Kairos Pharma, Ltd.
KAPA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.89M
Close$
$1.71
226.1% upside
Current Fair Value
226.1% upsideUndervalued by 226.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.89 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-2.1 |
| Beta | 1.44 |
| Outstanding Shares | 3,060,068 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.29 |
|---|---|
| PEG | 12.06 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.63
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.56
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.52%▲ 1.66% |
|---|---|
| Total Invested | $371,096▲ 8.66% |
| Investors Holding | 14▲ 3.00% |
About Kairos Pharma, Ltd.
4 employees
CEO: John S. Yu
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineer...